ASCO GI 2023 Virtual Poster Presentations

Program Content

Activities

  • Abstract
    Abstract: Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age stratified analysis.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Metastatic Colorectal Cancer
    Slides: Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: An age-stratified analysis
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Hepatocellular Carcinoma
    Abstract: Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 26, 2023

    Expires: January 25, 2024

  • Hepatocellular Carcinoma
    Slides: Real-world dosing of regorafenib in patients with  unresectable hepatocellular carcinoma (uHCC):  Final analysis of the prospective, observational  REFINE study
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 26, 2023

    Expires: January 25, 2024

  • AGOC
    Abstract: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • AGOC
    Slides: INTEGRATE IIa: Randomised double-blind Phase III  study of regorafenib versus placebo in refractory  advanced Gastro-Oesophageal Cancer (AGOC).
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Metastatic Colorectal Cancer
    Abstract: MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2023

    Expires: January 31, 2024

  • Metastatic Colorectal Cancer
    MOUNTAINEER-03 (NCT05253651) is a global, open-label,  randomized, phase 3 study of tucatinib with trastuzumab and  mFOLFOX6 versus standard of care for the first-line treatment of  HER2+ and RAS wild-type mCRC
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2023

    Expires: January 31, 2024

Faculty

cover img faculity

Barzi Afsaneh, MD, PhD

Director, AccessHope
City of Hope Comprehensive Cancer Center/AccessHope

cover img faculity

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

cover img faculity

Richard S. Finn, MD

Professor
Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California

cover img faculity

Nick Pavlakis, PhD, MBBS, FRACP

Medical Oncologist
Professor of Medicine
University of Sydney